

Stockholm, June 30, 2009

## Directed Share Issue in SCN to Settle Claim from Loan

**A consortium of investors have offered Scandinavian Clinical Nutrition AB (SCN) an interest free loan, payable with shares in SCN. The Board of SCN has accepted the offer, and therefore decided to issue a maximum of 3,200,000 shares in SCN at a price of SEK 1 per share to the consortium, by virtue of authorization from the 2009 Annual General Meeting.**

In accordance with SCN's previously communicated strategy aiming to strengthen the company's solidity and financial situation, the Board of SCN has accepted an offer from a consortium of investors regarding an interest free loan.

By virtue of and subject to registration of the authorization from the 2009 Annual General Meeting, the Board of SCN therefore today decided to carry out a directed share issue to the consortium at a price of SEK 1 per share. Through the share issue, the share capital of SCN will increase with a maximum of SEK 320,000 to a maximum of SEK 2,100,328.40, and the number of shares with a maximum of 3,200,000 to a maximum of 21,003,284 shares. In connection with the share issue, a prospectus will be submitted to the Swedish Financial Supervisory Authority for approval, since new shares will become subject to trade on a regulated market.

Given the current market conditions and the company's situation, the Board's assessment is that a directed share issue is the best measure to raise new capital to the company quickly and at market value.

**For more information, please contact:**

Ulf Söderberg, CEO, [us@scnutrition.com](mailto:us@scnutrition.com), +46 708 13 22 81

Jörn Erik Aas, Chairman of the Board, [jea@scnutrition.com](mailto:jea@scnutrition.com), +47 924 99 360

*Scandinavian Clinical Nutrition i Sverige AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker "SCN" on Oslo Axess ([www.osloaxess.no](http://www.osloaxess.no)) and NGM Equity ([www.ngm.se](http://www.ngm.se)). For more information, please visit [www.scnutrition.com](http://www.scnutrition.com).*